Ceritinib

Last Updated: 11/08/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 771 publications

2-Azabicyclo[3.2.1]octane-based ALK inhibitors inspired by aconitine scaffold remodeling: design, synthesis, and biological evaluation.

2-Azabicyclo[3.2.1]octane-based ALK inhibitors inspired by aconitine scaffold remodeling: design, synthesis, and biological evaluation.

Journal: Bioorganic chemistry

Published: September 02, 2026

Correction: Organizing pneumonia in ALK+ non-small cell lung cancer treated with ceritinib: a case report.

Correction: Organizing pneumonia in ALK+ non-small cell lung cancer treated with ceritinib: a case report.

Journal: Discover oncology

Published: August 26, 2026

Novel 2,4-Pyrimidinediamine Derivative as Potent EGFR Inhibitor for NSCLC Treatment.

Novel 2,4-Pyrimidinediamine Derivative as Potent EGFR Inhibitor for NSCLC Treatment.

Journal: Molecules (Basel, Switzerland)

Published: August 14, 2026

Clinical characteristics of ALK-positive NSCLC patients treated with sequential ALK-TKI therapies in a single-centre.

Clinical characteristics of ALK-positive NSCLC patients treated with sequential ALK-TKI therapies in a single-centre.

Journal: Lung cancer management

Published: July 27, 2026

Expert consensus on iruplinalkib for the treatment of ALK fusion gene positive non-small cell lung cancer (2026 edition)

Expert consensus on iruplinalkib for the treatment of ALK fusion gene positive non-small cell lung cancer (2026 edition)

Journal: Zhonghua zhong liu za zhi [Chinese journal of oncology]

Published: July 25, 2026

Predicting drug-drug interaction and optimal dosing regimens of rivaroxaban combined with ceritinib using physiologically based pharmacokinetic and pharmacodynamic modeling.

Predicting drug-drug interaction and optimal dosing regimens of rivaroxaban combined with ceritinib using physiologically based pharmacokinetic and pharmacodynamic modeling.

Journal: European journal of pharmacology

Published: July 19, 2026

Longitudinal Treatment Outcomes in Patients With Anaplastic Lymphoma Kinase-Rearranged Non-Small Cell Lung Cancer: Results From a Multinational Registry-Based Study in a Predominantly Western Population.

Longitudinal Treatment Outcomes in Patients With Anaplastic Lymphoma Kinase-Rearranged Non-Small Cell Lung Cancer: Results From a Multinational Registry-Based Study in a Predominantly Western Population.

Journal: JCO global oncology

Published: June 24, 2026

The ALK inhibitor lorlatinib attenuates lipopolysaccharide-induced neuroinflammation by inhibiting microglial activation and preserving blood-brain barrier integrity.

The ALK inhibitor lorlatinib attenuates lipopolysaccharide-induced neuroinflammation by inhibiting microglial activation and preserving blood-brain barrier integrity.

Journal: International immunopharmacology

Published: June 10, 2026

Rescuing a refractory Leiomyosarcoma: ALK-DCTN1 fusion as a gateway to long-term control with Ceritinib.

Rescuing a refractory Leiomyosarcoma: ALK-DCTN1 fusion as a gateway to long-term control with Ceritinib.

Journal: Gynecologic oncology reports

Published: June 01, 2026

Age-stratified adverse-event reporting signals of seven ALK/ROS1 tyrosine kinase inhibitors in FAERS: a disproportionality and time to onset study.

Age-stratified adverse-event reporting signals of seven ALK/ROS1 tyrosine kinase inhibitors in FAERS: a disproportionality and time to onset study.

Journal: Frontiers in pharmacology

Published: May 26, 2026

First-Line Alectinib Versus Ceritinib With or Without Brain Radiotherapy in ALK-Positive Non-Small Cell Lung Cancer with Brain Metastases: A Real-World Multicenter Study from Vietnam.

First-Line Alectinib Versus Ceritinib With or Without Brain Radiotherapy in ALK-Positive Non-Small Cell Lung Cancer with Brain Metastases: A Real-World Multicenter Study from Vietnam.

Journal: Thoracic cancer

Published: May 13, 2026

Identification of Der p1 inhibitors: Combining AI-based QSAR, molecular docking, molecular dynamics simulations and quantum physics.

Identification of Der p1 inhibitors: Combining AI-based QSAR, molecular docking, molecular dynamics simulations and quantum physics.

Journal: Computational biology and chemistry

Published: May 11, 2026

Showing 1-12 of 771

Last Updated: 11/08/2026